patent.fyi
Applications  /  US 2026/0356840
United States Patent Application Publication

US 2026/0356840 A1

Published
Nov 12, 2026
Filed
Apr 19, 2024
Earliest date on the face
Apr 21, 2023
Classification
C07D 487/04
First published here
Nov 20, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.4Cyano phenyl at R1

What ifWhat if R1 used a 3-cyano-4-methoxyphenyl group with an all-carbon aromatic ring?
Claim language“5- or 6-membered heteroaryl”

The phenyl ring provides a planar aromatic surface and carries methoxy at the 4-position. The nitrile at the 3-position places a hydrogen-bond acceptor outside the ring.

1.6Acyclic ether at R1

What ifWhat if R1 were an acyclic 2-methoxyethyl group?
Claim language“5- or 6-membered saturated or partially unsaturated heterocyclyl”

The —CH₂CH₂OCH₃ chain attaches through its first methylene and presents an ether oxygen as a hydrogen-bond acceptor. Rotation about the carbon–carbon single bond changes the orientation of the ether relative to the attachment point.

1.11Cyclobutane at the amide center

What ifWhat if the carbon next to the amide carbonyl formed part of a cyclobutane ring?
Claim language“form a cyclopropyl ring”

Three methylene groups complete a four-membered ring around the carbon that bears the amide carbonyl. The ring holds both carbon branches in a shared framework and adopts a puckered geometry.

1.12Thiazole at the amide nitrogen

What ifWhat if R2A were a 1,3-thiazol-2-yl group?
Claim language“R2A is phenyl or pyridyl”

Carbon 2 of the thiazole bonds directly to the amide nitrogen and presents a five-membered aromatic surface. The thiazole nitrogen supplies a hydrogen-bond acceptor adjacent to the attachment carbon.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Other field of use

Helicase control for analytical reagent testing

An analytical reagent test uses a triazolopyrimidinone with measured WRN inhibition as a low-activity control for recombinant WRN. A fluorescently labeled DNA duplex with a single-stranded loading tail reports unwinding after ATP addition. Each enzyme lot is tested with the compound and with matched solvent, and the difference between the two signals provides a measure of assay separation.

Component substitution

Oxetane substitution at the R1 position

An oxetan-3-yl group replaces the five- or six-membered saturated heterocyclyl group at R1. The bond to the triazolopyrimidinone runs through the oxetane carbon opposite the ring oxygen, and the remaining substituents match those of the reference compound. A matched-pair test measures aqueous solubility and WRN inhibition under identical conditions.

Sulfonamide substitution in the terminal side chain

An N-phenylsulfonamide replaces the N-phenylcarboxamide in an R2 side chain. The sulfonyl sulfur bonds directly to the side-chain carbon bearing the two RB groups, and the sulfonamide nitrogen bonds to phenyl and hydrogen. The triazolopyrimidinone core and the other attachment points match those of the reference compound for paired solubility and WRN inhibition measurements.

Parameter or scale variation

Miniaturized helicase concentration response assay

A 384-well plate holds 20 microliters per well of recombinant WRN, ATP, a fluorescent duplex DNA substrate, and test compound or control. A ten-point threefold dilution series starts at 30 micromolar compound, with dimethyl sulfoxide held at 0.5 percent in all wells. A plate reader measures fluorescence every 30 seconds for 20 minutes, and initial slopes normalized to solvent and enzyme-free controls yield the concentration response.

Combination with existing systems

Helicase inhibitors in isogenic cell assays

A triazolopyrimidinone concentration series is applied to paired human colorectal cell cultures consisting of a mismatch repair-deficient parental line and a derivative with the missing repair gene restored. The two cultures are plated in parallel with matched solvent controls and a baseline cell count at dosing. Automated nuclear counts after 72 hours provide growth-rate measurements for comparing the two cell backgrounds.

Automated or data-driven variant

Model guided selection of compound analogs

Software encodes each triazolopyrimidinone analog with a molecular fingerprint and links it to measured WRN inhibition and aqueous solubility. Separate Gaussian process models estimate both properties and their uncertainty for untested structures assembled from a catalog of available fragments. A batch selector ranks candidates by expected improvement in inhibition subject to a solubility threshold and updates both models as measured results enter the dataset.

Specific version of a part

Difluoro piperidine ring A

Ring A is 3,3-difluoropiperidine-1,4-diyl, with attachment points at N1 and C4. Two independently selected RA groups are both fluorine and occupy the same carbon at C3.

Oxa bridged bicyclic R1

R1 is 7-oxabicyclo[2.2.1]heptan-2-yl with zero additional substituents. One oxygen forms the one-atom bridge in the saturated seven-atom framework, and carbon 2 provides the attachment point.

Trans butenyl at R1

R1 is (E)-but-2-en-1-yl and attaches through its terminal methylene. The internal double bond places the attachment-side methylene and terminal methyl on opposite sides of the alkene.

Dimethylsulfamoyl as an RA group

One RA occurrence is —S(O)₂N(CH₃)₂, with both R groups set to methyl. The parent structure bonds directly to sulfur, and the two sulfonyl oxygens serve as hydrogen-bond acceptors.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2018/0028664 A1
Published
Feb 1, 2018
Filed
Aug 11, 2017
Class
A61K 47/10
Document BUS 2019/0125874 A1
Published
May 2, 2019
Filed
Oct 25, 2018
Class
A61K 47/183
Claim 1
Document A
Document B
1.1Ring A represents: a) a 4-7 membered saturated or partially unsaturated bivalent monocyclic ring system selected from carbocyclylene or heterocyclylene (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and 0 or 1 nitrogen atoms in addition to the 1-4 heteroatoms)
For example, in certain embodiments, the compound of (I) is of Formula (I-a), or a salt thereof, wherein at least one instance of R2 is each instance of R2 is optionally substituted C1-30 alkyl, wherein one or more methylene units of R2 are independently replaced with optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN) , —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(R
A · US 2018/0028664 A1 · ¶ 748
In certain embodiments, the heterocyclyl is substituted or unsubstituted, 3- to 7-membered, monocyclic heterocyclyl, wherein 1, 2, or 3 atoms in the heterocyclic ring system are independently oxygen, nitrogen, or sulfur, as valency permits.
B · US 2019/0125874 A1 · ¶ 310
1.2or b) a 4-12 membered saturated or partially unsaturated bivalent bicyclic ring system that is fused, bridged, or spirocyclic selected from carbocyclylene or heterocyclylene (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur)
A heterocyclyl group can either be monocyclic (“monocyclic heterocyclyl”) or polycyclic (e.g., a fused, bridged or spiro ring system such as a bicyclic system (“bicyclic heterocyclyl”) or tricyclic system (“tricyclic heterocyclyl”)), and can be saturated or can contain one or more carbon-carbon double or triple bonds.
A · US 2018/0028664 A1 · ¶ 783
1.3wherein Ring A is substituted with 0-4 independently selected RA substituents
each x is independently an integer between 0-30, inclusive; and each instance is G is independently selected from the group consisting of optionally substituted carbocyclylene, optionally substituted heterocyclylene, optionally substituted arylene, optionally substituted heteroarylene, —N(RN), —O—, —S—, —C(O)—, —C(O)N(RN)—, —NRNC(O)—, —NRNC(O)N(RN)—, —C(O)O—, —OC(O)—, —OC(O)O—, —OC(O)N(RN)—, —NRNC(O)O—, —C(O)S—, —SC(O)—, —C(═NRN)—, —C(═NRN)N(RN)—, —NRNC(═NRN)—, —NRNC(═NRN)N(R
A · US 2018/0028664 A1 · ¶ 750
1.4R1 is: a) a 5- or 6-membered heteroaryl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) substituted with 1 or 2 groups independently selected from C1-C6alkoxy, C3-C6cycloalkyl, and C3-C6cycloalkoxy
In some embodiments, a heteroaryl group is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”).
A · US 2018/0028664 A1 · ¶ 788
In certain embodiments, the heteroaryl is substituted or unsubstituted, 5- or 6-membered, monocyclic heteroaryl, wherein 1, 2, 3, or 4 atoms in the heteroaryl ring system are independently oxygen, nitrogen, or sulfur.
B · US 2019/0125874 A1 · ¶ 315
1.5wherein said 5- or 6-membered heteroaryl is further substituted with 0-3 independently selected RA
Unless otherwise specified, each instance of a heteroaryl group is independently unsubstituted (an “unsubstituted heteroaryl”) or substituted (a “substituted heteroaryl”) with one or more substituents.
B · US 2019/0125874 A1 · ¶ 316
1.6b) a 5- or 6-membered saturated or partially unsaturated heterocyclyl (having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), said heterocyclyl substituted with 0-2 groups independently selected from halogen, oxo, —NR2, optionally substituted C1-4 aliphatic, —OR, azetidinyl optionally substituted with 1 or 2 independently selected halogen, and pyrrolidinyl optionally substituted with 1 or 2 independently selected halogen
In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur.
A · US 2018/0028664 A1 · ¶ 784
1.7c) a 6-8 membered saturated or partially unsaturated bridged bicyclic heterocyclyl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur), said heterocyclyl substituted with 0-2 groups independently selected from halogen, oxo, —NR2, optionally substituted C1-4 aliphatic, —OR, azetidinyl optionally substituted with 1 or 2 independently selected halogen, and pyrrolidinyl optionally substituted with 1 or 2 independently selected halogen
1.8or d) a 3-7 membered optionally substituted carbocyclyl or an optionally substituted C2-C4alkenyl
In certain embodiments, aliphatic, alkyl, alkenyl, alkynyl, heteroaliphatic, heteroalkyl, heteroalkenyl, heteroalkynyl, carbocyclyl, heterocyclyl, aryl, and heteroaryl groups are optionally substituted. “Optionally substituted” refers to a group which may be substituted or unsubstituted (e.g., “substituted” or “unsubstituted” aliphatic, “substituted” or “unsubstituted” alkyl, “substituted” or “unsubstituted” alkenyl, “substituted” or “unsubstituted” alkynyl, “substituted” or
B · US 2019/0125874 A1 · ¶ 322
1.9RA is independently selected at each occurrence from the group consisting of halogen, —CN, —NO2, —OR, —SR, —NR2, —S(O)2R, —S(O)2NR2, —S(O)R, —S(O)NR2, —C(O)R, —C(O)OR, —C(O)NR2, —C(O)N(R)OR, —OC(O)R, —OC(O)NR2, —N(R)C(O)OR, —N(R)C(O)R, —N(R)C(O)NR2, —N(R)C(NR)NR2, —N(R)S(O)2NR2, —N(R)S(O)2R, and an optionally substituted C1-6 aliphatic group
In certain embodiments, R1a, R1b, R2, R3, R4a, and R4b are independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, halogen, hydroxyl, alkoxyl, carbamoyl, carbonyldioxyl, amido, thiohydroxyl, alkylthioether, amino, alkylamino, dialkylamino, trialkylamino, cyano, and ureido, each of which may be substituted, as permitted by valency, with at least one substituent selected from the group consisting of alkyl, alkenyl, alkynyl, amino, alkylamino, dial
B · US 2019/0125874 A1 · ¶ 85
1.10R2 is C(RB)2C(O)N(R)R2A
1.11RB is independently selected at each occurrence from hydrogen, —CH3, or —CH2CH3, or two RB taken together with the carbon to which they are attached form a cyclopropyl ring
1.12R2A is phenyl or pyridyl, each of which is optionally substituted with 1, 2, or 3 substituents independently selected from halogen, C1-C4alkyl, haloC1-C4alkyl, C3-C6cycloalkyl, haloC3-C6-cycloalkyl, —OH, —CN, C1-C4alkoxy, haloC1-C4alkoxy, —SF5, two substituents on adjacent atoms of the phenyl or pyridyl together with their intervening atoms form a 4- to 7-membered carbocyclyl fused to the phenyl or pyridyl, and two substituents on adjacent atoms of the phenyl or pyridyl together with their intervening atoms form a 4- to 7-membered heterocyclyl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) fused to the phenyl or pyridyl or R2A is 2-benzimidazolyl or 3-quinolinyl, each of which is optionally substituted with 1, 2 or 3 substituents independently selected from halogen, C1-4alkyl and —OH R3 is hydrogen, C1-C4alkyl, C3-C5cycloalkyl, C1-C4alkoxy, —NHR3A, —N(R3A)2 or C1-C4alkylthio each of which, besides hydrogen, is optionally substituted with —OH, 1-5 independently selected halogen, or C1-C4alkoxy each R3A is independently selected at each occurrence from C1-C4alkyl R4 is selected from one of a), b), and c): a) R4 is a Ring B that is selected from the group consisting of wherein * is a point of attachment to the carbonyl group that is bonded to Ring A in Formula I wherein: any substituents that are present on Ring B selected from R4A, R4B, R4C, R4D, R4E, and RF are each independently selected from hydrogen halogen —CN C1-C4alkyl C2-C4alkenyl C2-C4alkynyl C1-C4alkoxy haloC1-C4alkyl C1-C3alkyl substituted with —OH, —OCH3, or —OCH2CH3 haloC1-C4alkoxy C3-C6cycloalkyl C3-C6cycloalkoxy or NRC2 or R4A and R4B, along with their intervening atoms, join to form 4- to 7-membered optionally substituted carbocyclyl or optionally substituted heterocyclyl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) that is fused to Ring B any substituents that are present on Ring B selected from R4C, R4D, R4E, and R4F are each independently selected from hydrogen halogen —CN C1-C4alkyl C2-C4alkenyl C2-C4alkynyl haloC1-C4alkyl C1-C3alkyl substituted with —OH, —OCH3, or —OCH2CH3 haloC1-C4alkoxy C3-C6cycloalkyl C3-C6cycloalkoxy or NRC2 or R4B and R4C, along with their intervening atoms, join to form 4- to 7-membered optionally substituted carbocyclyl or optionally substituted heterocyclyl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) that is fused to Ring B any substituents that are present on Ring B selected from R4A, R4D, R4E, and R4F are each independently selected from hydrogen halogen —CN C1-C4alkyl C2-C4alkenyl C2-C4alkynyl haloC1-C4alkyl C1-C3alkyl substituted with —OH, —OCH3, or —OCH2CH3 haloC1-C4alkoxy C3-C6cycloalkyl C3-C6cycloalkoxy or NRC2 or R4C and R4D, along with their intervening atoms, join to form 4- to 7-membered optionally substituted carbocyclyl or optionally substituted heterocyclyl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) that is fused to Ring B any substituents that are present on Ring B selected from R4A, R4B, and R4E are each independently selected from hydrogen halogen —CN C1-C4alkyl C2-C4alkenyl C2-C4alkynyl haloC1-C4alkyl C1-C3alkyl substituted with —OH, —OCH3, or —OCH2CH3 haloC1-C4alkoxy C3-C6cycloalkyl C3-C6cycloalkoxy or NRC2 or R4E is halogen or —OH, and R4A, R4B, R4C, and R4D are each independently selected from hydrogen halogen —CN C1-C4alkyl C2-C4alkenyl C2-C4alkynyl haloC1-C4alkyl C1-C3alkyl substituted with —OH, —OCH3, or —OCH2CH3 haloC1-C4alkoxy C3-C6cycloalkyl C3-C6cycloalkoxy or NRC2 or R4E and R4A, along with their intervening atoms, join to form 5- to 6-membered optionally substituted heteroaryl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) that is fused to Ring B R4B, R4C, and R4D are each independently selected from hydrogen halogen —CN C1-C4alkyl C2-C4alkenyl C2-C4alkynyl haloC1-C4alkyl C1-C3alkyl substituted with —OH, —OCH3, or —OCH2CH3 haloC1-C4alkoxy C3-C6cycloalkyl C3-C6cycloalkoxy or NRC2 or R4F and R4A, along with their intervening atoms, join to form 5- to 6-membered optionally substituted heteroaryl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) that is fused to Ring B any substituents that are present on Ring B selected from R4B, R4C, and R4D are each independently selected from hydrogen halogen —CN C1-C4alkyl C2-C4alkenyl C2-C4alkynyl haloC1-C4alkyl C1-C3alkyl substituted with —OH, —OCH3, or —OCH2CH3 haloC1-C4alkoxy C3-C6cycloalkyl C3-C6cycloalkoxy or NRC2 RC is independently selected at each occurrence from hydrogen or C1-C4alkyl optionally substituted with —OH, —OCH3, or —OCH2CH3 or NRC2, taken in combination form a heterocyclic ring selected from azetidinyl, pyrrolidinyl, or piperidinyl, said heterocyclic ring optionally substituted with —CH3 or b) R4 is a 5-membered heteroaryl (having 1 heteroatom independently selected from nitrogen, oxygen, and sulfur and 0, 1, 2, or 3 additional ring nitrogen atoms) wherein said heteroaryl is optionally substituted with 0-4 groups independently selected from halogen, —OH, —CN, C1-C4alkyl, haloC1-C4alkyl, cycloC3-C6alkyl, and C1-C4alkoxy or c) R4 is a C1-C4alkyl, C1-C4alkoxy, or cycloC3-C6alkyl, each of which is substituted with 0-3 groups independently selected from halogen, —CN, —OH, C1-C4alkyl, C1-C4alkoxy, optionally substituted 5- to 6-membered heterocyclyl, and optionally substituted 5- to 6-membered heterocyclyloxy each R is independently hydrogen, or an optionally substituted C1-6 aliphatic group, an optionally substituted phenyl, an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclic ring, an optionally substituted 3-7 membered saturated or partially unsaturated heterocyclic ring (having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or an optionally substituted 5-6 membered heteroaryl ring (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) or two R groups on the same atom are taken together with the same atom to form an optionally substituted 4-7 membered saturated ring, partially unsaturated ring, or heteroaryl ring (wherein said 4-7 membered saturated ring, partially unsaturated ring, or heteroaryl ring, has 0-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur) with the proviso that one or two of the following provisions 1)-7) is satisfied, further provided that two of 1), 2), and 3) are not concurrently satisfied, and further provided that two of 4), 5), 6) and 7) are not concurrently satisfied: 1) R1 is a) a 5- or 6-membered heteroaryl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) substituted with 1 or 2 groups independently selected from C1-C6alkoxy, C3-C6cycloalkyl, or C3-C6cycloalkoxy wherein said 5- or 6-membered heteroaryl is further substituted with 0-3 independently selected RA 2) R1 is c) 6-8 membered saturated or partially unsaturated bridged bicyclic heterocyclyl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur), said heterocyclyl substituted with 0-2 groups independently selected from halogen, oxo, —NR2, optionally substituted C1-4 aliphatic, —OR, azetidinyl optionally substituted with 1 or 2 independently selected halogen, and pyrrolidinyl optionally substituted with 1 or 2 independently selected halogen 3) R1 is d) a 3-7 membered optionally substituted carbocyclyl or an optionally substituted C2-C4alkenyl 4) R4 is a 5-membered heteroaryl (having 1 heteroatom independently selected from nitrogen, oxygen, and sulfur and 0, 1, 2, or 3 additional ring nitrogen atoms) wherein said heteroaryl is optionally substituted with 0-4 groups independently selected from halogen, —OH, —CN, C1-C4alkyl, haloC1-C4alkyl, cycloC3-C6alkyl, and C1-C4alkoxy 5) R4 is selected from: 6) R4 is: wherein R4A and R4B, along with their intervening atoms, join to form 4- to 7-membered optionally substituted carbocyclyl or optionally substituted heterocyclyl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur), or wherein R4B and R4C along with their intervening atoms, join to form 4- to 7-membered optionally substituted carbocyclyl or optionally substituted heterocyclyl (having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur) 7) R4 is a C1-C4alkyl, C1-C4alkoxy, or cycloC3-C6alkyl, each of which is substituted with 0-3 groups independently selected from halogen, —CN, —OH, C1-C4alkyl, optionally substituted 5- to 6-membered heterocyclyl, and C1-C4alkoxy.
In some embodiments, an aryl group has 14 ring carbon atoms (“C14 aryl”; e.g., anthracyl). “Aryl” also includes ring systems wherein the aryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the radical or point of attachment is on the aryl ring, and in such instances, the number of carbon atoms continue to designate the number of carbon atoms in the aryl ring system.
A · US 2018/0028664 A1 · ¶ 786
Heteroaryl polycyclic ring systems can include one or more heteroatoms in one or both rings. “Heteroaryl” includes ring systems wherein the heteroaryl ring, as defined above, is fused with one or more carbocyclyl or heterocyclyl groups wherein the point of attachment is on the heteroaryl ring, and in such instances, the number of ring members continue to designate the number of ring members in the heteroaryl ring system. “Heteroaryl” also includes ring systems wherein the het
B · US 2019/0125874 A1 · ¶ 315

An empty cell means only that no passage was reproduced there.

Statements in these documents
However, even these “stealth” formulations have their limitations, including an inability to be repeatedly and frequently dosed, for example, over a period of days without loss of activity.
A · US 2018/0028664 A1 · ¶ 2
This disclosure provides, in part, novel lipid nanoparticles (LNP) and LNP formulations that are less susceptible to recognition and thus clearance, by the immune system.
A · US 2018/0028664 A1 · ¶ 6
In particular, there remains a need for delivery vehicles that form stable compositions, suitable for the delivery of therapeutic agents, such as mRNA, via nebulization.
B · US 2019/0125874 A1 · ¶ 3
Polymers of the invention can be used to prepare stable formulations (e.g., particles) for nebulization or aerosol delivery.
B · US 2019/0125874 A1 · ¶ 4
Cite aspatent.fyi, US 2026/0356840 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356840/, SHA-256 66396ad57e2225b5fdccd1bf664c5ec8f0e7151442f0d1ad7c6cdfae5886ba89
First published
Permanent addresshttps://patent.fyi/US20260356840/
Content fingerprint (SHA-256)66396ad57e2225b5fdccd1bf664c5ec8f0e7151442f0d1ad7c6cdfae5886ba89
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi